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To the Editor
We have read the manuscript by Zhang et al. with great interest
[1]. The results demonstrate an important role for CD147 in liver
injury. However, we have published results, which are not refer-
enced by Zhang et al. that appear to contradict some of their ﬁnd-
ings [2]. Our immunohistochemistry staining for CD147 shows a
pattern of expression consistent with hepatocyte and leukocyte
speciﬁc expression, but with negligible expression by hepatic
stellate cells (HSC) [2]. We used a well-characterised commercial
monoclonal antibody (MEM-M6/1) [2,3], whilst HAb18G, the
antibody used in the manuscript, is not commercially available
[1]. Confocal microscopy of CD147, using the antibody MEM-6/
1, shows localisation with the CK-18 marker of hepatocytes, but
not with a-smooth muscle actin (a-SMA) expressed by activated
HSC (Fig. 1). The staining presented in Fig. 1A of the manuscript
by Zhang et al. shows dense ﬁbrous bands in cirrhosis that are
strongly a-SMA positive, as expected [1]. However, the adjacent
panels in Fig. 1A of cirrhosis, stained with HAb18G for CD147,
have a different pattern of expression [1]. Therefore, we question
the association of CD147 and a-SMA expression in the liver. A
possible explanation is the heterogeneity in HSC populations as
discussed by Zhang et al. [1]. However, we have not observed
such heterogeneity; there is no signiﬁcant confocal microscopy
co-localisation of MEM-6/1-stained CD147 expressing cells and
a-SMA positive cells (Fig. 1). Further, we observe staining of
hepatocytes [2], which is not demonstrated in this manuscript
(Fig. 1). We have conﬁrmed these results by showing signiﬁcant
CD147 mRNA expression in primary isolated hepatocytes, which
is comparable to whole liver tissue expression. Our results are
in agreement with those published on the Human Protein Atlas
[4], and are consistent with data produced by other groups,
showing CD147 expression in hepatocyte-derived cell lines
[5,6]. A plausible explanation is, given that there are four major
CD147 isoforms combined with varying glycosylation modiﬁca-
tions of this widely expressed protein, that the different forms
of CD147 are selectively targeted by different antibodies. There-
fore, we believe the pattern of CD147 expression presented in
the manuscript should be interpreted as being speciﬁc for the
antibody used, and not generalised for all CD147 expression. It
would be useful to have both high and low power views of the
direct immunoﬂuorescent staining of a-SMA and CD147 co-local-
isation. Additionally, Zhang et al. show in panel 3D that in the
absence of CD147 overexpression, the HSC line LX-2 does not
express a-SMA [1]. However, in the original manuscript, in which
LX-2 where isolated [7], and subsequent articles, it has been
shown that LX-2 cells have an activated phenotype and do
express a-SMA [8]. Further, Zhang and colleagues have demon-
strated that activated LX-2 HSC in vivo lack signiﬁcant CD147
protein expression, when assessed by Western blot analysis
(Fig. 3D) [1]. Importantly, LX-2 exhibit multipotent behaviour
and characteristics of bone marrow-derived mesenchymal stem
cells and may not be the best model of in vivo HSC activation
[9]. We commend the authors for this important work but think
the role of CD147 in liver ﬁbrosis is considerably more complex
than that presented by Zhang et al. [1].
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Fig. 1. Confocal microscopy of CD147 with hepatocyte and hepatic stellate cell
(HSC) markers. Confocal microscopy was performed on cirrhotic tissue with
hepatocytes identiﬁed by CK-18 staining (red, in A) and HSC by a-SMA (red, in D).
CD147 was stained with the monoclonal antibody MEM-6/1 (green in B and E).
(C) The merged image of hepatocyte CK-18 and CD147 staining demonstrates co-
localisation. In panels D-F there is clear staining of HSC in the ﬁbrotic septa by a-
SMA (example marked with ⁄) and staining of CD147 (example marked by #). (F)
In the merge image of hepatic stellate cell and CD147 staining, there is no
signiﬁcant co-localisation.
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Reply to: ‘‘The role of CD147 in liver injury: The truth is in the details’’
To the Editor:
We greatly appreciate the letter by McLennan et al., which dis-
cusses our recently published article on the role of HAb18G/
CD147 promoting liver ﬁbrosis through activation of hepatic stel-
late cells (HSCs) [1].
In a chronically injured liver, caused by hepatitis B virus
(HBV), hepatitis C virus (HCV), alcohol or other factors, HSCs
are activated by inﬂammation mediators and differentiate into
myoﬁbroblasts, which play an important role in the development
of liver ﬁbrosis and cirrhosis. In China, HBV causes more cases of
liver cirrhosis than HCV, therefore our research interest focused
on HBV-related liver cirrhosis in our article [1]. The published
article by Shackel et al. using array analysis compared gene
expression of HCV-associated cirrhosis with autoimmune hepati-
tis-associated cirrhosis, showing a marked difference in the apop-
tosis-associated gene proﬁle, reﬂecting the fact that different
pathogens lead to different gene expression proﬁles.
However no data were shown in HBV-associated cirrhosis [2].
The antibody HAb18, for immunohistochemistry (IHC) of
human liver cirrhosis tissue, mentioned in our article, has already
been used for years in our laboratory, is qualiﬁed for Western
blot, IHC, immunoﬂuorescent staining, and has been granted
international patents (Patent Numbers: PCT/CN03/00188 and
PCT/CN2002/000356) [3,4]. The fragment F(ab0)2 of HAb18
labeled with 131I, registered as Licartin, has been approved for
the treatment of hepatocellular carcinoma (HCC) by the China
State Food and Drug Administration (Registration No.
S20050039) [5]. HAb18 combines with the Ig-C2 domain of iso-
form Basigin-2, which is the most predominant splice variant,
encoding the well-known EMMPRIN/CD147, but not with isoform
Basigin-3 [6,7].
Our previous IHC with commercial mouse anti-human CD147
antibody (NovoCastra) showed immunostaining in the tumor
compartment, but not in the stromal compartment, in HCC tis-
sues, which is consistent with our HAb18 staining in cirrhotic tis-
sues, where HAb18G/CD147 was absent in the ﬁbrous septa area
[8,1]. In the mouse liver ﬁbrosis model, CD147 expression in acti-
vated HSCs was shown with a commercial rat anti-mouse CD147
antibody (Abcam ab34016) by co-localization with alpha-smooth
muscle actin (a-SMA) in Disse’s space [1]. In our previous study
we showed that HAb18G/CD147 was expressed in hepatocytes
of cirrhotic and HCC tissues, consistent with Shackel’s paper
[9,2]. The a-SMA-positive cells represent a heterogeneous popu-
lation, including activated resident ﬁbroblasts, activated HSCs,
bone marrow-derived mesenchymal cells and ﬁbrocytes, hepato-
cytes or biliary epithelium-derived ﬁbroblasts by epithelial-mes-
enchymal transition, which means that not all of the a-SMA-
positive cells are derived from HSCs. Therefore, we identiﬁed
HSCs by reaction with a-SMA and their localization in the peris-
inusoidal space. McLennan et al. showed a positive staining of a-
SMA by immunoﬂuorescence in ﬁbrotic septa while no immuno-
reaction with a-SMA was observed in the perisinusoidal space
(Fig. 1D). Importantly, ﬁbrous septa composed of collagen have
a strong autoﬂuorescence, the speciﬁc ﬂuorescence is suggested
to be identiﬁed by blank and isotype controls. In Fig. 1C of the
McLennan’s study, the co-localization of CD147 with CK-18 was
observed in hepatocytes, but no CK-18 expression was observed
in some CD147 positive cells detected by green ﬂuorescence.
LX-2 cell line was originally isolated with property of a-SMA
expression detected by immunoﬂuorescence [10]. We also
observed a weak immunoﬂuorescent signal of a-SMA expression
in our work. However, we did not observe a detectable level of a-
SMA protein expression by Western blot, but mRNA expression
was detected by real-time PCR in untreated LX-2 cells. Stable
transfection with the CD147 gene in LX-2 cells induced a notable
a-SMA expression [1]. This may be due to a different detection
sensitivity and different sources of primary and secondary
antibodies.
In summary, we have reasons to believe that the HAb18 anti-
body used by us works properly and that the conclusions drawn
from these experiments are valid.
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